C4 therapeutics presents monotherapy data demonstrating proof of mechanism and early evidence of proof of concept from ongoing cft1946 phase 1 trial in braf v600 mutant solid tumors at the european society for medical oncology (esmo) congress 2024

Cft1946 is well-tolerated at all dose levels; no dose-limiting toxicities cft1946 achieves dose proportional pharmacokinetic exposure; successfully degrades braf v600 mutant protein early evidence of cft1946 monotherapy anti-tumor activity in patients who have progressed on or after braf inhibitor therapies; majority of patients demonstrated tumor reduction across v600 mutation types cft1946 global phase 1 trial continues to enroll; monotherapy and combination expansion cohorts advancing with additional data expected in 2025 c4t to host webcast today at 12:00 pm et; webcast link available  here watertown, mass., sept. 13, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced initial clinical data from the ongoing clinical trial of cft1946, an orally bioavailable small molecule degrader of braf v600 mutations in solid tumors.
CCCC Ratings Summary
CCCC Quant Ranking